A medicinal-chemistry study screened new compounds at several receptor targets. Binding activity and an anxiolytic-like behavioral result were distinct stages of the investigation.
Twenty chalcones were synthesized and assessed using ligand-displacement assays at benzodiazepine-associated GABA-A, serotonin, and opioid binding sites. Selected compounds then underwent mouse behavioral testing.
One methyl-hydroxychalcone showed an anxiolytic-like effect in the elevated plus maze. Other compounds showed antidepressant-like or antinociceptive activity in different assays.
A radioligand-displacement result does not by itself establish agonist action, clinical efficacy, or the mechanism of a behavioral change. The active compounds and endpoints differed across assays.
The study did not treat human anxiety or establish a safe replacement for a prescribed benzodiazepine. Forensic interpretation should preserve compound identity, target assay, species, and behavioral test. A shared screening target does not establish identical pharmacology, dependence potential, or impairment effects, and a mouse exploratory-behavior change remains a preclinical finding.
Original analysis of the supplied journal article, identified as PMC6430037.